Camelid TB Serology Quarterly Report: 1st October 2018 to 31st December 2018
Source: environment.data.gov.uk (2024-10-03)

Camelid TB Serology Quarterly Report. Camelid TB Serology Quarterly Report.

Camelid TB Serology
Quarterly Report
Number: 15
Report Period 1st October to 31st December 2018
Issued 09 January 2019

Submission Reason
Explanation
APHA /DEFRA
At Government expense
Parallel Test:
PAR-TB
TB breakdown herd with confirmed M. bovis infection (including Wales where Officially
TB Free Withdrawn [OTFW] status is determined on epidemiological grounds)
PAR-SUS
TB strongly suspected but not currently confirmed by laboratory culture – herd under
restrictions
PAR-TRC
Forward  tracing(s) from an M. bovis-infected camelid herd (includes camelid herds in
Wales only co-located on the same premises with infected cattle, sheep, deer, goats
& pigs)
Serial Test:
SER-CONT
Herd not under restriction but contiguous to a TB-infected herd
SER-COL
Herd not under restriction but co-located with an infected herd of cattle, deer, goats
etc. (Eng & Scot only)
SER-EPI
Herd not under restriction but TB tested due to an epidemiological link with a known
infected herd (e.g. back-tracing)
Commercial/Private
At Owner expense
SER-MVT
Pre- or post-movement test
SER-EXP 
Pre-export test
SER-DIAG
Diagnostic to exclude TB from a differential diagnoses in a herd not restricted (TB
strongly suspected)
SER-RHT
Monitoring - voluntary routine testing (herd nor restricted)
Quarterly Camelid Serology Report
Test Criteria
The camelid TB serology (antibody) test generally comprises two separate antibody tests in a test package that can be
applied flexibly to increase the sensitivity or specificity of the test as required, by using a parallel or serial test
interpretation respectively. The sensitivity and specificity values of combined antibody testing for camelids were described
under AHVLA Project FT1477 (see Rhodes et al., 2012) and re-assessed in May 2018 to show the following test
performance;
Table 1 – High Sensitivity / Parallel test options:
IDEXX /DPP VetTB
ENFER 2-SPOT/DPP VetTB
IDEXX/ENFER 2-SPOT
% Se
74
71
75
95% C.I.
65.4-82.6
62.1-79.9
66.5-83.5
% Sp
96
96.7
97.3
95% C.I.
93.8-98.2
95.8-99.4
95.4-99.1
Fishers Exact [2-sided] test showed no significant difference in sensitivity or specificity between any of these three test options.
Table 2 – High Specificity / Serial test options:
Fishers Exact [2-sided] test showed no significant difference in test sensitivity or specificity between these two test options.
ENFER 4-SPOT
IDEXX/DPP VetTB
% Se
60
56
95% C.I.
50.4-69.9
46.3-65.7
% Sp
99.66
100
95% C.I.
98.9-100
Rhodes, S., Holder, T., Clifford, D., Dexter, I., Brewer, J., Smith, N., Waring, L., Crawshaw, T., Gillgan, S., Lyashchenko,
K., Lawrence, J., Clarke, J., de la Rua-Domenech, R., Vordermeier, M., 2012. Evaluation of gamma interferon and
antibody tuberculosis tests in alpacas. Clin Vaccine Immunol 19, 1677-1683.

Quarterly Camelid Serology Report
09 Jan 2019
Table 1a
Country
No.
Samples
Tested
England
339
Wales
80
Non GB
1
Total for Q4
420
Number of Samples tested and Submission Reason  2018 Q4 (October - December)
Table 1b
Submission
Reason
No.
Samples
Tested
Parallel
PAR-SUS
7
PAR-TB
88
PAR-TRC
2
Parallel
Sum:
97
Serial
SER-COL
48
SER-CONT
266
Serial
Sum:
314
Commercial/Private Testing SER-DIAG
2
SER-EXP
1
SER-MVT
3
SER-RHT
3
Commercial/Private Testing
Sum:
9
Total for Q4
Sum:
420

Quarterly Camelid Serology Report
09 Jan 2019
Table 2a
Country
No.
Samples
Tested
England
1482
Wales
234
Non GB
20
Total for Q4
1736
Number of Samples tested and Submission Reason 2018 up to end of Q4 (January - December)
Table 2b
APHA/DEFRA
Submission
Reason
No.
Samples
Tested
Parallel
PAR-SUS
34
PAR-TB
194
PAR-TRC
5
Parallel
Sum:
233
Serial
SER-COL
165
SER-CONT
1220
SER-EPI
67
Serial
Sum:
1452
Commercial/Private Testing
SER-DIAG
3
SER-EXP
1
SER-MVT
40
SER-RHT
7
Commercial/Private Testing
Sum:
51
Total for 2018 up to end
of Q4
1736

Quarterly Camelid Serology Report
09 Jan 2019
Table 3a
Submissions Received and Test Positivity in 2018 Q4
Country
Submission
Reason
No.
Submissions
No. Samples
Tested
No.
Positive
Samples
% Positive
Samples
England
Parallel
PAR-SUS
1
7
2
28.6%
PAR-TB
2
44
1
2.3%
PAR-TRC
1
2
0
0
Parallel
4
53
3
5.7%
Serial
SER-COL
3
47
0
0
SER-CONT
18
231
1
0.4%
Serial
21
278
1
0.4%
Commercial/Private Testing
SER-DIAG
2
2
0
0
SER-MVT
1
3
0
0
SER-RHT
2
3
0
0
Commercial/Private Testing
5
8
0
0
England Total
30
339
4
1.2%
Wales
Parallel
PAR-TB
1
44
1
2.3%
Parallel
1
44
1
2.3%
Serial
SER-COL
1
1
0
0
SER-CONT
2
35
0
0
Serial
3
36
0
0
Wales Total
4
80
1
1.3%
Non GB
Commercial/Private Testing
SER-EXP
1
1
0
0
Commercial/Private Testing
1
1
0
0
Non GB Total
1
1
0
0
Totals for Q4
35
420
5
1.2 %
Test Positivity in 2018 Q4 (October - December)

Quarterly Camelid Serology Report
09 Jan 2019
Table 3b
Submissions Received and Test Positivity in 2018 up to the end of Q4
Country
Submission
Reason
No.
Submissions
No. Samples
Tested
No.
Positive
Samples
% Positive
Samples
England
Parallel
PAR-SUS
5
34
3
8.8%
PAR-TB
10
150
18
12.0%
PAR-TRC
2
5
3
60.0%
Parallel
17
189
24
12.7%
Serial
SER-COL
11
123
1
0.8%
SER-CONT
123
1,072
9
0.8%
SER-EPI
6
67
0
0
Serial
140
1,262
10
0.8%
Commercial/Private Testing
SER-DIAG
3
3
0
0
SER-MVT
6
21
0
0
SER-RHT
3
7
0
0
Commercial/Private Testing
12
31
0
0
England Total
169
1,482
34
2.3%
Wales
Parallel
PAR-TB
1
44
1
2.3%
Parallel
1
44
1
2.3%
Serial
SER-COL
7
42
0
0
SER-CONT
10
148
1
0.7%
Serial
17
190
1
0.5%
Wales Total
18
234
2
0.9%
Non GB
Commercial/Private Testing
SER-EXP
1
1
0
0
SER-MVT
1
19
0
0
Commercial/Private Testing
2
20
0
0
Non GB Total
2
20
0
0
Totals up to
end Q4
189
1,736
36
2.1 %
Test Positivity in 2018 up to end of Q4 (January - December)

Quarterly Camelid Serology Report
09 Jan 2019
Submissions Received in 2018 up to end of Q4
Analysis
Analysis Description
Q1
No.
samples
tested
Q2
No.
samples
tested
Q3
No.
samples
tested
Q4
No.
samples
tested
Totals up to end Q4
TC0503
Camelid TB Enferplex - 2
Spot
34
24
67
125
TC0603
Camelid TB Enferplex - 4
Spot
232
113
362
211
918
TC0615
Camelid TB DPP VetTB
antibody test
296
164
138
209
807
TC0867
Camelid TB Antibody
ELISA
282
164
118
142
706
Table 4: Number of samples Tested by Test Code